Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding ...

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

ESCO Technologies Inc. (NYSE:ESE) Q1 2026 Earnings Call Transcript

ESCO Technologies Inc. (NYSE:ESE) Q1 2026 Earnings Call Transcript February 5, 2026 ESCO Technologies Inc. misses on earnings ...